Enlicitide Adds an Oral Option for Hypercholesterolemia
Enlicitide is the first oral PCSK9 inhibitor approved for additional LDL-C lowering, offering a convenient option for adults with persistent hypercholesterolemia despite maximally tolerated statins.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.